All presentations are scheduled to be live, in-person presentations at the date and time specified below unless noted otherwise.  Program in progress.

*-Short talk from proffered abstract

Thursday, October 5

Welcome and Opening Keynote
Exploring the Role and Impact of Patients: A Collaborative Approach to Cancer Research

Friday, October 6

Plenary Session 1: Tumor Microenvironment and Immune Oncology I
Proffered Talks I
Plenary Session 2: Rare Ovarian Tumors
Plenary Session 3: Drug Discovery, Development, and Novel Pathways
Plenary Session 4: Early Detection and Prevention

Saturday, October 7

Plenary Session 5: Epigenetics and Epitranscriptomics
Closing Keynote
Proffered Talks II
Plenary Session 6: Tumor Microenvironment and Immune Oncology II

Thursday, October 5

Welcome and Opening Keynote
5-6 P.M.

Welcome from conference cochairs
Frances R. Balkwill, Barts Cancer Institute, Queen Mary University of London, London, England
Kunle Odunsi, University of Chicago Medicine Comprehensive Cancer Center, Chicago, Ilinois
Elizabeth M. Swisher, University of Washington, Seattle, Washington

Placing our bets to make a difference
David D.L. Bowtell, Peter MacCallum Cancer Center, Victoria, Australia

Exploring the Role and Impact of Patients: A Collaborative Approach to Cancer Research
Session Chair:Kunle Odunsi, University of Chicago, Chicago, Illnois and Elizabeth M. Swisher, University of Washington, Seattle, Washington

6-7 P.M.

Welcome and Introduction
Kunle Odunsi, University of Chicago Medicine Comprehensive Cancer Center, Chicago, Illinois

Patient advocacy: research, policy and community outreach
Marcie Paul, Michigan Ovarian Cancer Alliance, West Bloomfield, Michigan

A continuum of advocate involvement in research: from perfunctory to published
Kathleen Gavin, Minnesota Ovarian Cancer Alliance, Minneapolis

From patient to patient advocate
Kathleen Maxian, Ovarian Cancer Project, Buffalo, New York                                    

Future perspectives
Marcie Paul, Michigan Ovarian Cancer Alliance, West Bloomfield, Michigan
Kathleen Maxian, Ovarian Cancer Project, Buffalo, New York
Kathleen Gavin, Minnesota Ovarian Cancer Alliance, Minneapolis, Minnesota

Lightning talks I
7-7:30 P.M.

Anna Salvioni, University Cancer Institute of Toulouse, Toulouse, France
James W. Webber, Brigham and Women’s Hospital, Boston, Massachusetts
Yi Wen Kong, David. H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts
Emily S. Winn-Deen, Mercy BioAnalytics Inc., Natick, Massachusetts
Joanna Burdette, University of Illinois, Chicago, Illinois
Connor Sweetnam, Syapse, Inc, San Francisco, California
Quentin Chartreux, Cedars-Sinai Medical Center, Los Angeles, California
Rebecca L. Porter, Dana-Farber Cancer Institute, Boston, Massachusetts
Sergio Marchini, Humanitas Research Hospital, Rozzano, Italy

Poster Session A/Opening Reception
7:30-10 P.M.

Friday, October 6

Continental Breakfast
7-8 A.M.

Plenary Session 1: Tumor Microenvironment and Immune Oncology I
Session Chair: Frances Balkwill, Barts Cancer Institute, London, United Kingdom
8-9:30 A.M.

Fallopian tube precursors make tumors nervous
Ronny I. Drapkin, University of Pennsylvania, Philadelphia, Pennsylvania

Regional combating of immunosuppressive forces in the ovarian tumor microenvironment
Daniel J. Powell Jr., University of Pennsylvania, Philadelphia, Pennsylvania

Friend or foe: Reevaluating the therapeutic potential of monocytes and tumor-associated macrophages in ovarian cancer 
Oladapo O. Yeku, Massachusetts General Hospital, Boston, Massachusetts

Break
9:30-9:50 A.M.

Proffered Talks I
9:50-10:50 A.M.

Stable subclones and acquired genomic events present after treatment of HGSC*
Jaana Oikkonen. University of Helsinki, Helsinki, Finland.

Activation of the integrated stress response by NXP800, an orally available, clinical-stage, investigational agent in ARID1A-mutated, platinum resistant ovarian cancer*
Paul Workman. The Institute of Cancer Research, London, London, United Kingdom.

Half of CCNE1-amplified high-grade serous ovarian carcinomas are homologous recombination deficient and platinum-sensitive*
Liisa Kauppi. University of Helsinki, Helsinki, Finland.

The evolution of ovarian high grade serous carcinoma from STIC lesions*
Zhao Cheng. Ovarian Cancer Action Research Centre, Imperial College London, London, United Kingdom.

ZNFX1 is a master regulator for epigenetic reprograming of mitochondrial inflammasome signaling and pathogen mimicry in cancer cells*
Lora Stojanovic. Division of Translational Radiation Sciences, Department of Radiation Oncology, University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, Baltimore, United States.

A novel bispecific NK cell engager targeting FSHR and Siglec-7 displays potent anti-tumor immunity against ovarian cancer*
Devivasha Bordoloi. The Wistar Institute, Philadelphia, United States.

Plenary Session 2: Rare ovarian tumors
Session Chair: Kunle Odunsi, University of Chicago, Chicago, Illnois
11 A.m.-12:30 P.M.

Tumor heterogeneity of ovarian clear cell carcinoma
Ruby Yun-Ju Huang, National Taiwan University, Teipei, Taiwan

Rare ovarian cancers: the sequelae of specific interactions between cell contexts mutations and microenvironments
David G. Huntsman, University of British Columbia, Vancouver, BC, Canada

Epigenetic approaches for endometriosis-associated ovarian cancer
Rugang Zhang, MD Anderson Cancer Center, Houston, Texas

Lunch (On Own)
12:30-2 P.M.

Plenary Session 3: Drug Discovery, Development, and Novel Pathways
Session Chair: Elizabeth M. Swisher, University of Washington, Seattle, Washington
2-4 P.M.

Latest developments in targeting the DNA damage response in the clinic
Timothy A. Yap, MD Anderson Cancer Center, Houston, Texas

Advancing novel therapeutics through reverse translation
Sarah F. Adams, University of New Mexico, Albuquerque, New Mexico

Targeting AXL in platinum-resistant ovarian cancer: From the lab bench to Phase 3 trial   
Katherine C. Fuh, University of California San Francisco, San Francisco, California

Cell cycle checkpoint pathways as therapeutic target
Jung-min Lee, National Cancer Institute, Bethesda, Maryland

Break
4-4:20 P.M.

PLENARY SESSION 4: Early Detection and Prevention
Session Chair: Kunle Odunsi, University of Chicago, Chicago, Illnois
4:20-6:20 P.M.

Improving targeted precision prevention in ovarian cancer
Ranjit Manchanda, Barts Cancer Institute, Queen Mary University of London, London, England

Is salpingectomy as effective as bilateral salpingo-oophorectomy in preventing ovarian, fallopian tube, and peritoneal cancer? Let’s prove it!
Kathryn P. Pennington, University of Washington, Seattle, Washington

Opportunistic salpingectomy for ovarian cancer prevention
Gillian Hanley, University of British Columbia, Vancouver, BC, Canada

A liquid biopsy fingerprint of disease via nanoengineering
Daniel A. Heller, Memorial Sloan Kettering Cancer Center, New York, New York

Lightning talks II
6:30-7 P.m.

Dawn Cochrane, British Columbia Cancer Research Centre, BC, Canada
Veena K. Vuttaradhi, The University of Texas MD Anderson Cancer Center, Houston, Texas
Fernando Perez-Villatoro, University of Helsinki, Helsinki, Finland
Hao Nie, The University of Texas MD Anderson Cancer Center, Houston, Texas
Ada Junquera, University of Helsinki, Helsinki, Finland
Chi Lam Au Yeung, The University of Texas MD Anderson Cancer Center, Houston, Texas
Leonard G. Frisbie, University of Pittsburgh, Pittsburgh, Pennsylvania
Courtney A. Bailey, University of Colorado, Boulder, Colorado
Nan Zhang, The Wistar Institute, Philadelphia, Pennsylvania
Wade Barton. The University of Alabama, Birmingham, Alabama

Reception/poster session b
7-9:30 P.M.

Saturday, October 7

Continental Breakfast
7-8 A.M.

Plenary Session 5: Epigenetics and epitranscriptomics
Session Chair: Benjamin G. Neel, NYU Langone, New York, New York
8-9:30 A.M.

Epigenome targeting in ovarian cancer: preclinical models to clinic
Daniele Matei, Northwestern University, Chicago, Illinois

Gene regulation rewiring during high-grade serous ovarian cancer development
Kate Lawrenson, Cedars-Sinai Medical Center, Los Angeles, California

Targeting transposable elements with epigenetic modulators to reverse ovarian cancer immune evasion
Katherine B. Chiappanelli, The George Washington University School of Medicine and Health Sciences, Washington D.C.

Break
9:30-9:45 A.M.

Closing Keynote
9:45-10:30 A.M.

Kathleen R. Cho, University of Michigan Medical School, Ann Arbor, Michigan

Proffered Talks II
10:30-11:30 a.m.

Follicular fluid aids in cell adhesion, spreading and shows an age-dependent effect on DNA damage in fallopian tube epithelial cells*
Amrita Salvi. University of Illinois, Chicago, Chicago, United States.

Reconstructing the metastatic tumor microenvironment of high grade serous ovarian cancer using human multicellular in-vitro models*
Beatrice Malacrida. Queen Mary University of London, London, United Kingdom.

Dual targeting of IDO1/TDO2 inhibits tumor progression and attenuates the immune suppressive tumor microenvironment*
Benjamin Bitler. The University of Colorado, Denver, United States.

The role of cancer associated fibroblasts in ovarian cancer relapse*
Argha Ghosh. Indiana University School of Medicine – Bloomington, Bloomington, United States.

Patient-derived immunocompetent cultures reveal personalized immunotherapies and new treatment options for therapy resistant patients with high-grade serous ovarian cancer*
Anniina Färkkilä. University of Helsinki, Helsinki, Finland.

Proteogenomic analysis of enriched tumor epithelium identifies prognostic signatures and an increased dependency of homologous recombination proficient cells on bmi1 in high grade serous ovarian cancer*
Thomas Conrads. Inova Health System, Falls Church, United States.

Break
11:30-11:45 A.M.

Plenary Session 6: Tumor Microenvironment and Immune Oncology II
Session Chair: Kunle Odunsi, University of Chicago, Chicago, Illnois
11:45 A.m.-1:15 P.M.

B cells: the immune system’s secret weapon against ovarian cancer
Brad Nelson, University of British Columbia, Vancouver, BC, Canada

Spatial multiomics allows identifying the genomic and proteomic changes from borderline to low-grade serous cancer
Ernst R. Lengyel, University of Chicago, Chicago, Illinois

Mutational processes as determinants of immune evasion in ovarian cancer
Sohrab Shah, Memorial Sloan Kettering Cancer Center, New York, New York

Closing Remarks
1:15 P.M.

Elizabeth M. Swisher, University of Washington, Seattle, Washington